ENDRA Life Sciences Inc. (NDRA)
NASDAQ: NDRA · Real-Time Price · USD
4.590
-0.060 (-1.29%)
At close: Apr 2, 2026, 4:00 PM EDT
4.690
+0.100 (2.18%)
After-hours: Apr 2, 2026, 4:10 PM EDT
ENDRA Life Sciences Employees
ENDRA Life Sciences had 21 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
21
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$334,639
Market Cap
5.47M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 21 | 0 | - | 21 | 0 |
| Dec 31, 2023 | 21 | 0 | - | 21 | 0 |
| Dec 31, 2022 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2021 | 22 | 4 | 22.22% | 22 | 0 |
| Dec 31, 2020 | 18 | 3 | 20.00% | 18 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Inotiv | 2,046 |
| XWELL | 312 |
| MDxHealth | 312 |
| Exagen | 220 |
| Precipio | 60 |
| bioAffinity Technologies | 57 |
| Insight Molecular Diagnostics | 49 |
| Advanced Biomed | 31 |
NDRA News
- 4 days ago - ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Business Wire
- 11 days ago - ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value - Business Wire
- 5 weeks ago - ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care - Business Wire
- 4 months ago - ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use - Business Wire
- 4 months ago - ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker - Business Wire
- 4 months ago - ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results - Business Wire
- 5 months ago - ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA - Business Wire
- 5 months ago - ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings - Business Wire